Cardiokol Overview
Cardiokol is a privately owned digital telehealth company that develops voice-based markers and methods for monitoring and screening heart rhythm disorders in large at-risk populations. The company utilizes proprietary technology that is implemented in speech platforms such as landlines, smart phones, smart speakers, and voice assistants. Cardiokol offers low-cost, long-term, and user-friendly monitoring solutions, applicable for monitoring at-risk populations of older adults (65+).
Cumulative Funding Raised Over Time ($)
$8.0MSep 2019
Latest News
growth-positive
"תגידו אההההה": קרדיוקול מסייעת לזהות שבץ באמצעות...
Cardiokol, an Israeli health tech startup, has developed a technology that uses voice-based markers to detect strokes. The technology allows for the identification of atrial fibrillation, a common heart rhythm disorder, even before other symptoms appear. The company has conducted clinical trials with over 700 participants, most of them in Israel, and the results indicate success in identifying the disease. Cardiokol has raised $8 million in a seed funding round from KAMET and several private investors. The company is now preparing for a Series A funding round, aiming to raise $15 million.
InvestmentExpand
growth-positive
Nine digital health pioneers to join Bayer's G4A program
Bayer has accepted nine companies into its Digital Health Partnership Program, focusing on mental health, cardiometabolic and renal diseases, radiology, and womens health. Four startups have joined the program through Bayers G4A Growth Track, receiving €100,000 each for market uptake and mentoring. The funded startups include Cardiokol, Acorai, Pollie, and RCubeHealth. Additionally, five companies have been selected for commercial partnerships through Bayers G4A Advanced Track, including Liva Healthcare, Cordio Medical, Nines, Woebot Health, and Zed Technologies. Bayer aims to accelerate R&D in digital health through these investments. The companys G4A program has supported over 150 European healthcare technology companies through partnerships, collaborations, and investments.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $8M |
| Last funding | $8M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 2 |
Team Members
5
Employees: 1-10
Web & Social Links
| Website | www.cardiokol.com |
Locations
Airport City, Israel
Photos & Videos
3 item(s)
Cardiokol Business
Business models
B2B
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesDigital HealthcarePatient Remote MonitoringTarget Customer
ConsumersDemographics & FamilySeniorsHealthcare & Life SciencesHealthcareProvidersCore Technology
Artificial IntelligenceMachine LearningVoice & Speech RecognitionSemiconductors & ElectronicsDigital Signal ProcessorTags (18)
deep-neural-networksdisease-management5g-networkssignal-processingmachine-learningstrokeseniorsbiomarkersheart-diseasesdata-analyticsartificial-intelligencedigital-healthcareheart-failurevoice-analyticscardiologypreventionremote-monitoringtelehealthGeographic Markets
United StatesEuropeCardiokol Financials
$8M
Total funding
Undisclosed
Capital raised
$8M
Last funding
Seed
Funding stage
2
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$8.0MSep 2019
Private Equity Funding
Seed
Sep 2019
$8M
Kamet Ventures (Lead)
,
KYTO
Non-Equity Funding
GrantEvent
Undisclosed
Cardiokol Lifecycle
Cumulative Funding Raised Over Time
$8.0MSep 2019
All Events
Seed
Sep 2019
$8M
Kamet Ventures (Lead)
,
KYTO
GrantEvent
Undisclosed
Cardiokol News
2 articles
growth-positive
"תגידו אההההה": קרדיוקול מסייעת לזהות שבץ באמצעות...
Cardiokol, an Israeli health tech startup, has developed a technology that uses voice-based markers to detect strokes. The technology allows for the identification of atrial fibrillation, a common heart rhythm disorder, even before other symptoms appear. The company has conducted clinical trials with over 700 participants, most of them in Israel, and the results indicate success in identifying the disease. Cardiokol has raised $8 million in a seed funding round from KAMET and several private investors. The company is now preparing for a Series A funding round, aiming to raise $15 million.
InvestmentExpand
growth-positive
Nine digital health pioneers to join Bayer's G4A program
Bayer has accepted nine companies into its Digital Health Partnership Program, focusing on mental health, cardiometabolic and renal diseases, radiology, and womens health. Four startups have joined the program through Bayers G4A Growth Track, receiving €100,000 each for market uptake and mentoring. The funded startups include Cardiokol, Acorai, Pollie, and RCubeHealth. Additionally, five companies have been selected for commercial partnerships through Bayers G4A Advanced Track, including Liva Healthcare, Cordio Medical, Nines, Woebot Health, and Zed Technologies. Bayer aims to accelerate R&D in digital health through these investments. The companys G4A program has supported over 150 European healthcare technology companies through partnerships, collaborations, and investments.
Partners
Cardiokol Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 9 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 14 classification IDs that could be used for matching.
Cardiokol Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 99/100 |
| Missing | markets |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 515700359 |
| Phone | +97233732233 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wain@gmail.com |
| Last update | 2022-06-23T00:00:00.000Z |
| Created | 2018-02-21T00:00:00.000Z |
| Claimed | Yes |